Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients ...

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit the Swiss ... with a full impairment of 2.12 billion Swiss francs ($2.4 billion) in ...

In this article, we aim to review patient perspectives on integration of healthcare for HIV, type 2 diabetes and hypertension. Methods The framework for scoping reviews developed by Arksey and ...

Danish start-up Fuse Vectors has received $5.2 million in preseed financing to further develop their gene therapy technology. The company has developed a cell-free platform for producing adeno ...

The fact that autoimmune and inflammatory diseases can occur despite an apparent loss of immunocompetence caused by HIV infection is a true paradox. [3] In general, one would expect that illnesses ...

Based on these findings, we established a gene regulatory network specific to HIV-1-infected cells ... HIV-1 genome using the STARsolo (v. 2.7.1a). We adjusted the mapping percentage parameter from 50 ...

The study, published Oct. 11 in Science Immunology, removes one more barrier to developing a vaccine for HIV, and potentially other diseases such as malaria and cancer. Daniel Malouli, Ph.D ...

Here, we demonstrate a portable multiplex RT-PCR device designed for fast and cost-effective testing of HIV-1 and HIV-2 using finger-prick blood in LMICs. It features on-site RNA extraction and ...

15 The map in figure 1 illustrates the countries eligible for inclusion. Studies written in languages other than English, and studies describing aspects of HSV-2 other than interactions with HIV ...

Although not formally defined as a neglected tropical disease, HIV-2 infection attracts remarkably little attention or investment compared with its pandemic relative, HIV-1. Antiretroviral therapy ...